Therapy Areas: Devices
Pneuma Respiratory names new president and chief medical officer
10 April 2018 -

Pneuma Respiratory, Incorporated, a company that has developed PNEUMAHALER, claimed to be the first fully digital breath activated inhaler, has named Dr Steven Kesten as its president and chief medical officer, it was reported on Monday.

Dr Kesten brings extensive pharmaceutical and medical device experience to a management team familiar with launching new companies and leading them to public exits, including two healthcare companies. He joins the company as it pursues FDA approval for a portfolio of therapeutics targeting asthma and chronic obstructive pulmonary disease (COPD). Dr Kesten's experience as the VP of Respiratory Products at Boehringer Ingelheim included key national and international roles in clinical development, regulatory and commercialisation.

Prior to Dr Kesten's tenure as an executive at Boehringer Ingelheim, he was a staff pulmonologist at Toronto General Hospital and Toronto Western Hospital, as well as a faculty member of the University of Toronto. In his last year in Toronto, he was appointed medical director of the Toronto Lung Transplant Program. He subsequently joined Rush Presbyterian St. Luke's Medical Center as the medical director of the Rush Advanced Lung Disease and Lung Transplant Program and was appointed as an associate professor of medicine at Rush Medical College before joining Boehringer Ingelheim Pharmaceuticals. In recent years, Dr Kesten served as the chief medical officer and executive vice president of Cytori Therapeutics and chief medical officer and vice president of Uptake Medical corp.

During his career he has published over 160 peer-reviewed publications.



Related Headlines